Clinical trial
PRS-343 in HER2-Positive Solid Tumors
NCT03330561
Study timeline
Study start (actual)2017-09-13Date precision: day
Registry last updated2024-04-22
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-positive Breast Cancerunresolved
HER2-positive Gastric Cancerunresolved
HER2-positive Bladder Cancerunresolved
HER2-positive Solid Tumorunresolved
Interventions
PRS-343DRUG
Sponsors & collaborators
Pieris Pharmaceuticals, Inc.lead sponsor
Mapped research locations
San AntonioTexas, United States2New YorkNew York, United States1HoustonTexas, United States1BaltimoreMaryland, United States1NashvilleTennessee, United States1PittsburghPennsylvania, United States1Washington D.C.District of Columbia, United States1TucsonArizona, United States1Santa MonicaCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03330561 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.